No quarterly revenue total was found in GALECTIN THERAPEUTICS INC.'s SEC filings.
Galectin Therapeutics Inc. (GALT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $13.3 million in cash and investments and $118,000 in total debt.
Revenue
—
Net income
$-9.11M
-21.2% vs year-ago quarter
Operating cash flow
$-2.44M
+63.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.14
-16.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
100.85M
+57.4% vs year-ago quarter
Net cash
$13.15M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Norcross, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1133416
- Former names
- PRO PHARMACEUTICALS INC (until May 26, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.0M | -$4.1M | -$3.4M | -$4.2M | -$4.6M |
| Net income | -$9.1M | -$5.0M | -$5.5M | -$8.2M | -$7.5M |
| Diluted EPS | -$0.14 | -$0.08 | -$0.09 | -$0.13 | -$0.12 |
| Operating cash flow | -$2.4M | -$3.9M | -$6.0M | -$3.5M | -$6.6M |
| Total assets | $14.8M | $15.8M | $19.5M | $12.9M | $15.6M |
| Total liabilities | $151.7M | $146.0M | $145.7M | $136.4M | $132.8M |
| Stockholders' equity | -$138.6M | -$132.0M | -$127.9M | -$125.3M | -$118.9M |
| Cash and investments | $13.3M | $14.1M | $17.7M | $11.5M | $13.8M |
| Total debt | $118,000 | $6,000 | $22,000 | $37,000 | $52,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 13, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Aug 4, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 23, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
All 1000 Galectin Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.